NZ606996A - Thorium-227 for use in radiotherapy of soft tissue disease - Google Patents

Thorium-227 for use in radiotherapy of soft tissue disease

Info

Publication number
NZ606996A
NZ606996A NZ606996A NZ60699604A NZ606996A NZ 606996 A NZ606996 A NZ 606996A NZ 606996 A NZ606996 A NZ 606996A NZ 60699604 A NZ60699604 A NZ 60699604A NZ 606996 A NZ606996 A NZ 606996A
Authority
NZ
New Zealand
Prior art keywords
thorium
soft tissue
radiotherapy
tissue disease
excluding
Prior art date
Application number
NZ606996A
Other languages
English (en)
Inventor
Roy Larsen
Oyvind Bruland
Original Assignee
Algeta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0308731.9A external-priority patent/GB0308731D0/en
Application filed by Algeta As filed Critical Algeta As
Publication of NZ606996A publication Critical patent/NZ606996A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
NZ606996A 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease NZ606996A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308731.9A GB0308731D0 (en) 2003-04-15 2003-04-15 Method of radiotherapy
NZ595758A NZ595758A (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Publications (1)

Publication Number Publication Date
NZ606996A true NZ606996A (en) 2014-08-29

Family

ID=35385222

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ606996A NZ606996A (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease
NZ543044A NZ543044A (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease
NZ595758A NZ595758A (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ543044A NZ543044A (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease
NZ595758A NZ595758A (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Country Status (18)

Country Link
EP (1) EP1617876B1 (enExample)
JP (2) JP5006032B2 (enExample)
KR (2) KR20060015507A (enExample)
CN (1) CN100586484C (enExample)
AU (1) AU2004229218B2 (enExample)
BR (1) BRPI0409387B8 (enExample)
CA (1) CA2522148C (enExample)
CY (1) CY1115407T1 (enExample)
DK (1) DK1617876T3 (enExample)
EA (1) EA008195B1 (enExample)
ES (1) ES2486845T3 (enExample)
IL (1) IL171148A (enExample)
MX (1) MXPA05010804A (enExample)
NO (1) NO332931B1 (enExample)
NZ (3) NZ606996A (enExample)
PL (1) PL1617876T3 (enExample)
PT (1) PT1617876E (enExample)
ZA (1) ZA200507983B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1617876T3 (pl) * 2003-04-15 2015-03-31 Algeta Asa Tor-227 do zastosowania w radioterapii choroby tkanek miękkich
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
WO2018109667A1 (en) 2016-12-15 2018-06-21 Nestec Sa Compositions and methods that modulate white blood cells or neutrophils in a companion animal
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053196T3 (es) * 1989-06-19 1994-07-16 Akzo Nv Metodo para la produccion de un radioinmunoconjugado.
WO1993020852A2 (en) * 1992-04-13 1993-10-28 The Dow Chemical Company Macrocyclic chelating agents, chelates and conjugates thereof
CN1073860C (zh) * 1998-08-20 2001-10-31 中国核动力研究设计院 用于骨肿瘤治疗或诊断的放射性药物药盒的制备方法
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
HUP0203743A2 (en) * 2000-02-25 2003-02-28 R Keith Frank Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
ITMI20022411A1 (it) * 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
PL1617876T3 (pl) * 2003-04-15 2015-03-31 Algeta Asa Tor-227 do zastosowania w radioterapii choroby tkanek miękkich

Also Published As

Publication number Publication date
JP2012051942A (ja) 2012-03-15
KR101274867B1 (ko) 2013-06-13
KR20110022743A (ko) 2011-03-07
NO20055390D0 (no) 2005-11-15
AU2004229218A1 (en) 2004-10-28
EP1617876B1 (en) 2014-05-14
AU2004229218B2 (en) 2009-05-07
DK1617876T3 (da) 2014-07-21
PL1617876T3 (pl) 2015-03-31
JP5468597B2 (ja) 2014-04-09
JP2006523664A (ja) 2006-10-19
NZ595758A (en) 2013-02-22
EA200501456A1 (ru) 2006-06-30
ZA200507983B (en) 2007-03-28
EP1617876A1 (en) 2006-01-25
BRPI0409387A (pt) 2006-04-18
BRPI0409387B1 (pt) 2021-05-11
CN100586484C (zh) 2010-02-03
NZ543044A (en) 2010-04-30
CA2522148C (en) 2010-07-13
PT1617876E (pt) 2014-08-04
CY1115407T1 (el) 2017-01-04
CN1805760A (zh) 2006-07-19
HK1094150A1 (zh) 2007-03-23
NO20055390L (no) 2006-01-16
MXPA05010804A (es) 2006-03-09
CA2522148A1 (en) 2004-10-28
IL171148A (en) 2013-12-31
KR20060015507A (ko) 2006-02-17
BRPI0409387B8 (pt) 2021-05-25
NO332931B1 (no) 2013-02-04
EA008195B1 (ru) 2007-04-27
ES2486845T3 (es) 2014-08-19
JP5006032B2 (ja) 2012-08-22

Similar Documents

Publication Publication Date Title
WO2002102299A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
NZ527283A (en) Modified antibodies and methods of use
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
WO2002082041A3 (en) Production and use of novel peptide-based agents for use with bi-specific antibodies
WO2004073656A3 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
NZ611563A (en) Human antibodies that bind human il-12 and methods for producing
AR048098A1 (es) Conjugados de caliqueamicina
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
WO2000056774A8 (en) Methods of using bioelastomers
WO2001085203A3 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
WO2004111199A3 (en) Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
IL172982A0 (en) Antibodies and ca6 antigen specific cytotoxic conjugates and pharmaceutical compositions containing the same
TR200101673A2 (tr) Düz kas hücrelerinin sıkışmasıyla ilgili hastalıkların tedavisindeki kompozisyonlar için biyokimyasal maddeler.
NO20021701L (no) Fremgangsmåte for fremstilling av et konjugat av polyglutamat og et terapeutisk middel
WO1999066951A3 (en) Use of bi-specific antibodies for pre-targeting diagnosis and therapy
BRPI0411200A (pt) método de tratamento de cáncer, métodos de tratamento de paciente humano, artigo industrializado e kit de tratamento de cáncer
WO2004032857A8 (en) Antibody therapy
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
NZ606996A (en) Thorium-227 for use in radiotherapy of soft tissue disease
WO2003089593A3 (en) Adjuvant enhanced immunotherapy
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
AU2003244762A1 (en) Methods and compositions for intravesical therapy of bladder cancer
WO2004080284A3 (en) Antibody-targeted photodynamic therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 15 APR 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20150303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2018 BY CPA GLOBAL

Effective date: 20170318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2019 BY CPA GLOBAL

Effective date: 20180322

LAPS Patent lapsed